Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease

Movement Disorders

Volumn 27, Issue 1, 2012, Pages 132-135

  De Lau, Lonneke M L ^a,b   Verbaan, Dagmar ^a   Marinus, Johan ^a   Heutink, Peter ^c   Van Hilten, Jacobus J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

COMT; Dyskinesia; Genetics; Parkinson's disease

Indexed keywords

CATECHOL METHYLTRANSFERASE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; METHIONINE; VALINE;

ADULT; ALLELE; ARTICLE; DNA POLYMORPHISM; DYSKINESIA; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL;

AGED; ANTIPARASITIC AGENTS; CATECHOL O-METHYLTRANSFERASE; COHORT STUDIES; DYSKINESIA, DRUG-INDUCED; DYSKINESIAS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; METHIONINE; MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; VALINE;

EID: 84855924547     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23805     Document Type: Article

References (17)

1. D'souza UM, Craig IW. Functional polymorphisms in dopamine and serotonin pathway genes. Hum Mutat 2006; 27: 1-13.
2. Lee MS, Lyoo CH, Ulmanen I, Syvanen AC, Rinne JO. Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease. Neurosci Lett 2001; 298: 131-134.
3. Contin M, Martinelli P, Mochi M, Riva R, Albani F, Baruzzi A. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease. Mov Disord 2005; 20: 734-739.
4. Watanabe M, Harada S, Nakamura T, et al. Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease. Neuropsychobiology 2003; 48: 190-193.
5. Jenner P. Molecular mechanisms of L-dopa-induced dyskinesia. Nat Rev Neurosci 2008; 9: 665-677.
6. Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol 2006; 63: 205-209.
7. Bialecka M, Kurzawski M, Klodowska-Duda G, Opala G, Tan EK, Drozdzik M. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications. Pharmacogenet Genomics 2008; 18: 815-821.
8. Litvan I, Bhatia KP, Burn DJ, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord 2003; 18: 467-486.
9. Verbaan D, Marinus J, Visser M, et al. Cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007; 78: 1182-1187.
10. Marinus J, Visser M, Stiggelbout AM, et al. A short scale for the assessment of motor impairments and disabilities in Parkinson's disease: the SPES/SCOPA. J Neurol Neurosurg Psychiatry 2004; 75: 388-395.
11. Gosso MF, de Geus EJ, Polderman TJ, Boomsma DI, Heutink P, Posthuma D. Catechol-O-methyl transferase and dopamine D2 receptor gene polymorphisms: evidence of positive heterosis and gene-gene interaction on working memory functioning. Eur J Hum Genet 2008; 16: 1075-1082.
12. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord 2007; 22: 1379-1389.
13. Rylander D, Parent M, O'sullivan SS, et al. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol 2010; 68: 619-628.
14. Zappia M, Annesi G, Nicoletti G, et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch Neurol 2005; 62: 601-605.
15. Sharma JC, Bachmann CG, Linazasoro G. Classifying risk factors for dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 2010; 16: 490-497.
16. Williams-Gray CH, Hampshire A, Barker RA, Owen AM. Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype. Brain 2008; 131: 397-408.
17. Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2, and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry 2008; 13: 544-556.